A study published in the Journal of the American Medical Association (JAMA) indicated that the use of Abbott Laboratories‘ XIENCE™ V Everolimus Eluting Coronary Stent System in patients with coronary artery disease resulted in a 50% reduction in vessel renarrowing. It also showed an observed 42% reduction in major adverse cardiac events (MACE) at one year in the patients using XIENCE V Everolimus Eluting Coronary Stent System, as compared to the TAXUS® Paclitaxel-Eluting Coronary Stent System.